Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies | Zendy

Federico Cappuzzo | Zendy; Ross A. Soo | Zendy; Maximilian J. Hochmair | Zendy; Martin Schüler | Zendy; Kwok Chi Lam | Zendy; G. Stehle | Zendy; A. Cseh | Zendy; Robert M. Lorence | Zendy; Stephan Linden | Zendy; Nicole D Forman | Zendy; Wolfgang Hilbe | Zendy; Abdul Rahman Jazieh | Zendy; ChunMing Tsai | Zendy

Open Access

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies

Author(s) -

Federico Cappuzzo,

Ross A. Soo,

Maximilian J. Hochmair,

Martin Schüler,

Kwok Chi Lam,

G. Stehle,

A. Cseh,

Robert M. Lorence,

Stephan Linden,

Nicole D Forman,

Wolfgang Hilbe,

Abdul Rahman Jazieh,

ChunMing Tsai

Publication year - 2018

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2017-0666

Subject(s) - afatinib , medicine , erlotinib , gefitinib , oncology , lung cancer , clinical trial , carcinoma , epidermal growth factor receptor , cancer

Aim: A global afatinib named patient use program in non-small-cell lung carcinoma (NSCLC) commenced in 2010. Materials & methods: Eligible NSCLC patients had progressed after clinical benefit on prior erlotinib/gefitinib and/or had activating EGFR/HER2 mutations, exhausted all other treatments, and were ineligible for afatinib trials. Results: Data, as of January 2016, were reported on 3966 heavily pretreated NSCLC patients (41 countries; six continents). Among 2595/3966 (65.4%) patients with tumor EGFR status, 2407 (92.8%) were EGFR mutation positive. Median time to treatment failure (2862/3966 [72.2%] patients with available data) was 4.4 months. Among 1141/2862 (39.9%) patients with response reported, objective response rate was 23.4% (267/1141). Safety findings were as expected. Conclusion: Time to treatment failure durations and objective response rates were encouraging.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research